Memorial Sloan-Kettering

The firm is moving into a larger facility after its first full year of profitability and planning new hires to support its plans to bring liquid biopsy kits through the FDA.

The projects are organized by the Eliminate Cancer Initiative, the National Brain Tumor Society, and the Pediatric Brain Tumor Foundation.

Researchers at Memorial Sloan Kettering Cancer Center identified clinically actionable germline mutations in 8.5 percent of about 2,700 unselected lung cancer patients.

Over to You

A Memorial Sloan Kettering Cancer Center VP is giving the institute $1.4 million he made from representing it on a biotech board, the New York Times and ProPublica report.

Researchers find that fecal microbiome transplants restore gut bacteria in cancer patients who underwent antibiotic treatment for a stem cell transplant.

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

The tool, called Cerebro, significantly outperformed other publicly available methods, including in the less-trafficked areas of the genome that are now relevant for TMB immunotherapy prediction.

MSKCC investigators showed that truncated mRNAs can inactivate tumor suppressor genes, fueling cancer development even without the presence of DNA mutations.

In a pair of commentaries, researchers critique last year's paper reporting the use of CRISPR/Cas9 to correct a mutation in viable human embryos.

This Week in Cell

In Cell this week: structural variants affecting regulatory loci in prostate cancer, immune features in the breast cancer microenvironment, and more.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.